Novavax, Inc.

NVAX

$10.83

Updated: 23/09/2026, 07:05:54

Market Cap

$1.78B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for NVAX

Company Profile

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

USD

NASDAQ

CEO: John Charles Jacobs

Employees: 749

https://www.novavax.com

Asset Summaries

Latest generated summaries for NVAX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for NVAX.

Share price: $10.83
Market cap: $1.78B
Exchange: NASDAQ
Currency: USD
CEO: John Charles Jacobs
Employees: 749
IPO date: 05/12/1995
Beta: 2.45
Last dividend: $0.00
Day range: $10.23 – $11.09
52-week range: $6.20 – $11.97
1-day performance: 4.03%
1-year performance: 74.68%
Current drawdown (1Y): -9.52%
CIK: 0001000694
CUSIP: 670002401
ISIN: US6700024010
Created: 07/12/2025, 05:31:48
Last update: 23/09/2026, 07:05:54

Track Novavax, Inc. with an AI analyst

See which prediction-market events move NVAX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to NVAX from your Railway `news_articles` table.

Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 04/06/2026, 15:11:52

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

PRNewsWire • STOCK • 01/06/2026, 18:00:00

Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 14/05/2026, 00:20:42

NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum

Zacks Investment Research • STOCK • 07/05/2026, 14:16:42

Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 06/05/2026, 16:21:17

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Zacks Investment Research • STOCK • 01/05/2026, 20:45:23

Shah Capital intends to vote against Novavax's board nominees, executive compensation

Reuters • STOCK • 08/04/2026, 08:08:09

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research • STOCK • 23/03/2026, 10:55:39

Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/03/2026, 19:00:14

Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • STOCK • 03/03/2026, 17:22:16

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Seeking Alpha • STOCK • 27/02/2026, 13:11:24

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

Zacks Investment Research • STOCK • 27/02/2026, 10:30:19